AlphAIalphai — Financial news for AI agents
stocktitan.netSEP 31 min read$RXST

RxSight (RXST) exec’s stock sale only covers taxes

RxSight (RXST) reported that Chief Business Development Officer Eric Weinberg converted 5,370 RSUs into shares and sold 2,041 shares at $6.96 to cover taxes. Weinberg retains indirect holdings and significant RSUs set to vest by 2029. No discretionary sale or 10b5-1 plan was involved.

Original reporting
stocktitan.net
Published Sep 3, 2026, 1:39 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 2:03 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$RXST
Neutral
high confidence
Mentioned
$RXST
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$RXSTNeutralLow
01

Why it matters

The disclosed sale is modest and tax‑related, offering little new insight for traders.

02

Market read

Limited relevance; the transaction size is trivial and does not suggest a change in company fundamentals.

03

What to watch

Potential future RSU vesting schedule could affect dilution if the executive departs.

Relevance 4/10Novelty 2/10Timing: post‑trade September 2, 2026

Background

Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$RXSTNeutralHigh confidence
Context

Chief Business Development Officer Eric Weinberg sold 2,041 shares at $6.96 to cover tax withholding after RSU vesting.

Expected impact

No material price impact expected.

Evidence & confidence

The sale is small relative to market cap and is disclosed as a tax withholding transaction, not a discretionary divestment.

Market effects

Sector

None; the transaction is company‑specific.

Regional

None; limited to RxSight shareholders.

Global

None

Counterpoint

What could challenge this read

Even small insider sells can signal concerns, but the disclosed tax purpose weakens this argument.

Key entities

  • individual
    Eric Weinberg

    Chief Business Development Officer of RxSight

Read at source← All news

Related articles

AUG 17
$ALCMed

Adjustable precision vision post-cataract surgery

Alcon and RxSight announced a non-exclusive collaboration to develop adjustable presbyopia-correcting intraocular lenses. RxSight’s Light Adjustable Lens is described as FDA-approved and adjustable after surgery via non-invasive light treatments. Alcon will lead global commercialization, RxSight will handle development and manufacturing and receive royalties on net sales.

nzoptics.co.nz3 min
AUG 14
$RXSTMedAI 8/10

RxSight (RXST) Q2 2026 Earnings Call Transcript

RxSight (RXST) held its Q2 2026 earnings call. The company said it withdrew full-year 2026 guidance and will resume formal guidance in early 2027. Q2 total revenue was $33.7M, including $6.5M from an Alcon collaboration. Product sales were $27.2M, down 19% YoY, with a Q2 net loss of $12.1M.

yahoo.com6 min
AUG 5
$RXSTMedAI 8/10

RxSight, Inc. (RXST): Results of Operations and Financial Condition

RxSight, Inc. (RXST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 RXSIGHT, INC. REPORTS SECOND QUARTER 2026 RESULTS AND PROVIDES UPDATE ON 2026 OUTLOOK Aliso Viejo, Calif. – August 5, 2026 – RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended June 30, 2026, and provided an update on its 2026 financia

SEC EDGAR 8-K6 min
AUG 1
$RXSTMed

RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer

RxSight, Inc. (NASDAQ: RXST) announced a leadership transition effective July 20, 2026. Aziz Mottiwala will become President and CEO, succeeding Ron Kurtz, M.D., who will remain Chief Medical Officer. Kurtz will also resign from the board, with Mottiwala appointed in his place. The company cited commercial and clinical continuity around its light adjustable lens technology.

hrtoday.in3 min
JUL 20
$RXSTMed

RxSight Lands Tarsus Commercial Leader as CEO

RxSight (Nasdaq: RXST) appointed Aziz Mottiwala as CEO on July 15, replacing Dr. Ron Kurtz, who becomes chief medical officer. Mottiwala previously served as Tarsus Pharmaceuticals’ chief commercial officer. RXST shares rose 7.2% to $5.63 after the news. The article cites RXST’s forecast cuts and a Bank of America price target cut to $6.50, plus an Alcon partnership with $60 million upfront and up to $140 million in milestones.

ocbj.com6 min
JUL 11
$RXSTMedAI 8/10

RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook

RxSight (NASDAQ:RXST) reported Q2 sales of 11 Light Delivery Devices (LDDs) and one LDD rental, lowering sales 20% and leaving an installed base of 1,166 units. Cash, cash equivalents and short-term investments were about $209M. It revised 2026 revenue to $140M-$160M, including $110M-$120M RxSight sales and $30M-$40M Alcon collaboration revenue, and raised gross margin outlook to 73%-75%.

yahoo.com4 min